rs113846542 - PRKG1

Magnitude 4.5 · 1 study on file

Reported associations

• Molecular determinants of thrombosis recurrence risk across venous thromboembolism subtypes. - Blood (2025) · Munsch G, Thibord F, Bezerra OC, Brody JA, van Hylckama Vlieg A, Gourhant L, Chen MH, Samaria F, Germain M, Caro I, Suchon P, Olaso R, Wiggins KL, Saut N, Besse C, Goumidi L, Bacq D, Harrington LB, Boland A, Emmerich J, Smadja DM, Lemarié CA, Danckwardt S, Debette S, Deleuze JF, Jacqmin-Gadda H, Rodger MA, Gagnon F, Rosendaal FR, Johnson AD, Smith NL, Couturaud F, Morange PE, Trégouët DA · PubMed 40811855

  Venous thromboembolism (VTE) is a frequent (annual incidence of 1-2 per 1000 individuals) and potentially life-threatening (case-fatality rate up to 10%) disease. VTE is associated with serious short-term and long-term complications, including a recurrence rate approaching 20% within 5 years. Anticoagulant therapy, the mainstay of VTE treatment, drastically reduces the risk of early VTE recurrence, but it exposes patients to a substantial risk of bleeding. We analyzed the genomic architecture of VTE recurrence using data from 6355 patients across 8 cohorts (including 1775 recurrences), enriched by subgroup analyses, according to sex and clinical manifestation of first VTE, which led to the identification of 28 molecular markers. Through genome-wide association studies, we identified 1 locu

Auto-generated from study metadata. AI-synthesised commentary is added when this entry is regenerated through content-service's LLM mode.